A British study found that a combination of transvaginal ultrasound and CA-125 protein blood test is unlikely to spot ovarian cancer at an early stage. The study suggests that ovarian cancer screening should not be administered to women who are not at high risk of developing the disease, except those who are included in a trial designed to enhance screening techniques.

Related Summaries